Expanded Access to Upadacitinib

Sponsor
AbbVie
Study ID
NCT04159597
Status
Available

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Upadacitinib — DRUG
    Upadacitinib will be administered as oral solution.

Study Details

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Key Dates

First listed
Nov 12, 2019
Status verified
Aug 2026

Central Contacts

Find similar trials

Nationwide
Atopic dermatitis / eczema trialsCrohn's disease trialsHidradenitis suppurativa trialsPsoriatic arthritis trialsRheumatoid arthritis trialsLupus (SLE) trialsUlcerative colitis trialsDermatology trialsRheumatology trialsAutoimmune disease trialsGastroenterology trialsInflammatory bowel disease trialsMusculoskeletal disorders trials

Related Studies